Macrophage cholesterol efflux to plasma and HDL in subjects with low and high homocysteine levels: A FIELD substudy

Atherosclerosis

Volumn 219, Issue 1, 2011, Pages 259-265

  Maranghi, Marianna ^a   Hiukka, Anne ^a   Badeau, Robert ^b   Sundvall, Jouko ^b   Jauhiainen, Matti ^b   Taskinen, Marja Riitta ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Atherosclerosis; Fenofibrate; HDL; Homocysteine

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; CHOLESTEROL; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; PHOSPHOLIPID TRANSFER PROTEIN; PLACEBO; PRE BETA HIGH DENSITY LIPOPROTEIN;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOAM CELL; HUMAN; HUMAN CELL; MACROPHAGE; MALE; PARTICLE SIZE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; ARYLDIALKYLPHOSPHATASE; CELLS, CULTURED; CHOLESTEROL; CHOLESTEROL, HDL; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FENOFIBRATE; FOAM CELLS; HIGH-DENSITY LIPOPROTEINS, PRE-BETA; HOMOCYSTEINE; HUMANS; MACROPHAGES; MALE; MIDDLE AGED; PARTICLE SIZE; PHOSPHOLIPID TRANSFER PROTEINS;

EID: 80052004313     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.05.018     Document Type: Article

References (36)

1. Keech A., Simes R.J., Barter P., et al. FIELD study investigators Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366(9500):1849-1861.
2. ACCORD Study Group, Ginsberg H.N., Elam M.B., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010, 362(17):1563-1574.
3. Knopp R.H., Walden C.E., Warnick G.R., Albers J.J., Ginsberg J., McGinnis B.M. Effect of fenofibrate treatment on plasma lipoprotein lipids, high-density lipoprotein cholesterol subfractions and apolipoproteins B, AI, AII, and E. Am J Med 1987, 83(5B):75-84.
4. Taskinen M.R., Sullivan D.R., Ehnholm C., et al. FIELD study investigators. Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocystei-ne and creatinine in patients with type 2 diabetes treated with fenofibrate. Arterioscler Thromb Vasc Biol 2009, 29(6):950-955.
5. Hiukka A., Leinonen E., Jauhiainen M., et al. Long term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus. Diabetologia 2007, 50(10):2067-2075.
6. Lagrost L., Dengremont C., Athias A., et al. Modulation of cholesterol efflux from Fu5AH hepatoma cells by the apolipoprotein content of high density lipoprotein particles. Particles containing various proportions of apolipoproteins A-I and A-II. J Biol Chem 1995, 270(22):13004-13009.
7. Syvänne M., Castro G., Dengremont C., et al. Cholesterol efflux from Fu5AH hepatoma cells induced by plasma of subjects with or without coronary artery disease and non-insulin-dependent diabetes: importance of LpA-I:A-II particles and phospholipid transfer protein. Atherosclerosis 1996, 127(2):245-253.
8. Arsenault B.J., Arsenault B.J., Lemieux I., et al. HDL particle size and the risk of coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. Atherosclerosis 2009, 206(1):276-281.
9. Dierkes J., Westphal S., Luley C. Serum homocysteine increases after therapy with fenofibrate or bezafibrate. Lancet 1999, 354(9174):219-220.
10. Legendre C., Caussé E., Chaput E., Salvayre R., Pineau T., Edgar A.D. Fenofibrate induces a selective increase of protein-bound homocysteine in rodents: a PPARalpha-mediated effect. Biochem Biophys Res Commun 2002, 295(5):1052-1056.
11. Mikael L.G., Genest J., Rozen R. Elevated homocysteine reduces Apolipoprotein A-I expression in hyperhomocysteinemic mice and in males with coronary artery disease. Circ Res 2006, 98(4):564-571.
12. Hoogeveen E.K., Kostense P.J., Jakobs C., et al. Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn Study. Circulation 2000, 101(13):1506-1511.
13. Ferretti G., Bacchetti T., Masciangelo S., Bicchiega V. Effect of homocysteinylation on high density lipoprotein physico-chemical properties. Chem Phys Lipids 2010, 163(2):228-235.
14. Holven K.B., Aukrust P., Retterstøl K., et al. The antiatherogenic function of HDL is impaired in hyperhomocysteinemic subjects. J Nutr 2008, 138(11):2070-2075.
15. Jauhiainen M., Ehnholm C. Determination of human plasma phospholipid transfer protein mass and activity. Methods 2005, 36(2):97-101.
16. Kleemola P., Freese R., Jauhiainen M., Pahlman R., Alfthan G., Mutanen M. Dietary determinants of serum paraoxonase activity in healthy humans. Atherosclerosis 2002, 160(2):425-432.
17. Taskinen M.R., Taskinen M.R., Kuusi T., Helve E., Nikkilä E.A., Yki-Järvinen H. Insulin therapy induces antiatherogenic changes of serum lipoproteins in noninsulin-dependent diabetes. Arterioscler Thromb Vasc Biol 1988, 8(2):168-177.
18. Pérusse M., Pascot A., Després J.P., Couillard C., Lamarche B A new method for HDL particle sizing by polyacrylamide gradient gel electrophoresis using whole plasma. J Lipid Res 2001, 42(88):1331-1334.
19. Soderlund S., Soro-Paavonen A., Ehnholm C., Jauhiainen M., Taskinen M.R. Hypertriglyceridemia is associated with prebeta-HDL concentrations in subjects with familial low HDL. J Lipid Res 2005, 46(8):1643-1651.
20. Nakanishi J., Vikstedt R., Söderlund S., et al. Serum, but not monocyte macrophage foam cells derived from low HDL-C subjects, displays reduced cholesterol efflux capacity. J Lipid Res 2009, 50:183-192.
21. Kritharides L., Christian A., Stoudt G., Morel D., Rothblat G.H. Cholesterol metabolism and efflux in human THP-1 macrophages. Arterioscler Thromb Vasc Biol 1998, 18(10):1589-1599.
22. Joseph J., Handy D.E., Loscalzo J. Quo Vadis: Whither homocysteine research. Cardiovasc Toxicol 2009, 9:53-56.
23. Ogata M., Tsujita M., Hossain M.A., et al. On the mechanism for PPAR agonists to enhance ABCA1 gene expression. Atherosclerosis 2009, 205(2):413-419.
24. Chinetti G., Lestavel S., Fruchart J.C., Clavey V., Staels B. Peroxisome proliferator-activated receptor alpha reduces cholesterol esterification in macrophages. Circ Res 2003, 92(2):212-217.
25. Guerin M., Le Goff W., Frisdal E., et al. Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux. J Clin Endocrinol Metab 2003, 88(8):3738-3746.
26. Fournier N., Cogny A., Atger V., et al. Opposite effects of plasma from human apolipoprotein A-II transgenic mice on cholesterol efflux from J774 macrophages and Fu5AH hepatoma cells. Arterioscler Thromb Vasc Biol 2002, 22(4):638-643.
27. Favari E., Calabresi L., Adorni M.P., et al. Small discoidal pre-beta1 HDL particles are efficient acceptors of cell cholesterol via ABCA1 and ABCG1. Biochemistry 2009, 48(46):11067-11074.
28. Huuskonen J., Olkkonen V.M., Jauhiainen M., Ehnholm C. The impact of phospholipid transfer protein (PLTP) on HDL metabolism. Atherosclerosis 2001, 155(2):269-281.
29. Bouly M., Masson D., Gross B., et al. Induction of the phospholipid transfer protein gene accounts for the high density lipo-protein enlargement in mice treated with fenofibrate. J Biol Chem 2001, 276(28):25841-25847.
30. Filippatos T.D., Liberopoulos E.N., Kostapanos M., et al. The effects of orlistat and fenofibrate, alone or in combination, on high-density lipo-protein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome. Diabetes Obes Metab 2008, 10(6):476-483.
31. Miida T., Sakai K., Ozaki K., et al. Bezafibrate increases prebeta 1-HDL at the expense of HDL2b in hypertriglyceridemia. Arterioscler Thromb Vasc Biol 2000, 20(11):2428-2433.
32. Tsimihodimos V., Gazi I., Filippatos T., et al. Plasma triglyceride levels and body mass index values are the most important deter-minants of prebeta-1 HDL concentrations in patients with various types of primary dyslipidemia. Atherosclerosis 2010, 208(2):506-511.
33. Phuntuwate W., Suthisisang C., Koanantakul B., Chaloeiphap P., Mackness B., Mackness M. Effect of fenofibrate therapy on paraoxonase1 status in patients with low HDL-C levels. Atherosclerosis 2008, 196(1):122-128.
34. Tsimihodimos V., Kakafika A., Tambaki A.P., et al. Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins. J Lipid Res 2003, 44(5):927-934.
35. Billecke S., Draganov D., Counsell R., et al. Human serum para-oxonase(pon1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos 2000, 28(11):1335-1342.
36. Kontush A., Chapman M.J. Antiatherogenic function of HDL particle subpopulations: focus on an-tioxidative activities. Curr Opin Lipidol 2010, 21(4):312-318.